TY - JOUR
T1 - Inhibition of Human Coronaviruses by Antimalarial Peroxides
AU - Ghosh, Ayan Kumar
AU - Miller, Halli
AU - Knox, Konstance
AU - Kundu, Madhuchhanda
AU - Henrickson, Kelly J.
AU - Arav-Boger, Ravit
N1 - Funding Information:
We thank Natalie Thornburg, Ph.D., CDC Principal Investigator, and the UTMB World Reference Center for Emerging Viruses and Arboviruses (WRCEVA) for providing SARS-CoV-2 strain USA_WA1/2020. We thank Jonathan Vennerstrom, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, for providing the ozonides (OZ277, OZ418, and OZ439) for the study.
Publisher Copyright:
© Authors 2021
PY - 2021/7/9
Y1 - 2021/7/9
N2 - As the toll of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues, efforts are ongoing to identify new agents and repurpose safe drugs for its treatment. Antimalarial peroxides have reported antiviral and anticancer activities. Here, we evaluated the in vitro activities of artesunate (AS) and two ozonides (OZ418 and OZ277) against human α-coronavirus NL63 and β-coronaviruses OC43 and SARS-CoV-2 in several cell lines. OZ418 had the best selectivity index (SI) in NL63-infected Vero cells and MK2 cells. The overall SI of the tested compounds was cell-type dependent. In OC43-infected human foreskin fibroblasts, AS had the best cell-associated SI, ≥17 μM, while the SI of OZ418 and OZ277 was ≥12 μM and ≥7 μM, respectively. AS did not inhibit SARS-CoV-2 in either Vero or Calu-3 cells. A comparison of OZ418 and OZ277 activity in SARS-CoV2-infected Calu-3 cells revealed similar EC50 (5.3 μM and 11.6 μM, respectively), higher than the EC50 of remdesivir (1.0 ± 0.1 μM), but the SI of OZ418 was higher than OZ277. A third ozonide, OZ439, inhibited SARS-CoV-2 efficiently in Vero cells, but compared to OZ418 in Calu-3 cells, it showed higher toxicity. Improved inhibition of SARS-CoV-2 was observed when OZ418 was used together with remdesivir. Although the EC50 of ozonides might be clinically achieved in plasma after intravenous administration, sustained virus suppression in tissues will require further considerations, including drug combination. Our work supports the potential repurposing of ozonides and calls for future in vivo models.
AB - As the toll of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues, efforts are ongoing to identify new agents and repurpose safe drugs for its treatment. Antimalarial peroxides have reported antiviral and anticancer activities. Here, we evaluated the in vitro activities of artesunate (AS) and two ozonides (OZ418 and OZ277) against human α-coronavirus NL63 and β-coronaviruses OC43 and SARS-CoV-2 in several cell lines. OZ418 had the best selectivity index (SI) in NL63-infected Vero cells and MK2 cells. The overall SI of the tested compounds was cell-type dependent. In OC43-infected human foreskin fibroblasts, AS had the best cell-associated SI, ≥17 μM, while the SI of OZ418 and OZ277 was ≥12 μM and ≥7 μM, respectively. AS did not inhibit SARS-CoV-2 in either Vero or Calu-3 cells. A comparison of OZ418 and OZ277 activity in SARS-CoV2-infected Calu-3 cells revealed similar EC50 (5.3 μM and 11.6 μM, respectively), higher than the EC50 of remdesivir (1.0 ± 0.1 μM), but the SI of OZ418 was higher than OZ277. A third ozonide, OZ439, inhibited SARS-CoV-2 efficiently in Vero cells, but compared to OZ418 in Calu-3 cells, it showed higher toxicity. Improved inhibition of SARS-CoV-2 was observed when OZ418 was used together with remdesivir. Although the EC50 of ozonides might be clinically achieved in plasma after intravenous administration, sustained virus suppression in tissues will require further considerations, including drug combination. Our work supports the potential repurposing of ozonides and calls for future in vivo models.
KW - SARS-CoV-2
KW - artemisinins
KW - combination
KW - coronaviruses
KW - ozonides
KW - remdesivir
UR - http://www.scopus.com/inward/record.url?scp=85105043981&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105043981&partnerID=8YFLogxK
U2 - 10.1021/acsinfecdis.1c00053
DO - 10.1021/acsinfecdis.1c00053
M3 - Article
C2 - 33783182
AN - SCOPUS:85105043981
SN - 2373-8227
VL - 7
SP - 1985
EP - 1995
JO - ACS Infectious Diseases
JF - ACS Infectious Diseases
IS - 7
ER -